Biotech Values

[Titan V]

SGEN to Acquire CASC, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline
https://www.businesswire.com/news/home/20180131005494/en/Seattle-Genetics-Acquire-Cascadian-Therapeutics-Adding-Late-Stage

-Enhances Seattle Genetics’ Portfolio of Solid Tumor Programs with Potential Rapid Registrational Pathways-

-Provides Global Rights to Pivotal Phase 2 Program in Development for HER2-Positive Metastatic Breast Cancer-

-Conference Call Today at 8:30 a.m. ET-

BOTHELL, Wash. & SEATTLE--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc. (Nasdaq:CASC) today announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay $10.00 per share in cash, or approximately $614 million